10-K: ENDRA Life Sciences Inc. Faces Financial Hurdles Despite Promising Technology

ENDRA Life Sciences Inc.'s 10-K filing reveals ongoing financial challenges and operating losses, despite advancements in its TAEUS technology and a strategic shift towards metabolic disease management.

Summary

• ENDRA Life Sciences Inc. is developing its TAEUS technology platform, focusing on metabolic diseases and GLP-1 drug management.
• The company is implementing significant changes to its go-to-market strategy, targeting pharmaceutical companies, high-end primary care networks, bariatric clinics, and primary care physicians.
• ENDRA's primary focus is to establish key biomarkers for metabolic diseases management with specific focus on the emerging GLP-1 therapies.
• The company plans to implement a new low barrier-to-entry, multi-year, subscription-based business model with monthly recurring revenue.
• As of December 31, 2024, ENDRA had an accumulated deficit of $103.4 million and cash reserves of $3.2 million.
• The company's independent registered public accounting firm has raised substantial doubt about its ability to continue as a going concern.
• ENDRA is actively exploring additional sources of liquidity, including public or private equity offerings, debt financings, and corporate collaborations.
• The company recorded a net loss of $11.5 million for the year ended December 31, 2024, compared to a net loss of $10.1 million for the year ended December 31, 2023.
• ENDRA is working towards obtaining regulatory approvals for its TAEUS applications, including a De Novo request to the FDA.
• The company is subject to risks associated with doing business outside of the United States, including changes in political and economic conditions, regulatory requirements, and currency exchange rates.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While there are positive aspects such as the strategic shift and potential market opportunities, the financial challenges and going concern uncertainty weigh heavily, resulting in a slightly negative overall outlook.

Positives

• ENDRA is shifting its focus to metabolic diseases and GLP-1 drug management, which aligns with a growing market.
• The company plans to implement a new low barrier-to-entry, multi-year, subscription-based business model with monthly recurring revenue.
• ENDRA is working towards obtaining regulatory approvals for its TAEUS applications, including a De Novo request to the FDA.
• The company successfully concluded both an ISO 13485 Audit and an MDR Quality System Audit in November 2024, setting the groundwork for a future CE Mark Technical Documentation Audit in 2026.

Negatives

• As of December 31, 2024, ENDRA had an accumulated deficit of $103.4 million and cash reserves of $3.2 million.
• The company's independent registered public accounting firm has raised substantial doubt about its ability to continue as a going concern.
• The company recorded a net loss of $11.5 million for the year ended December 31, 2024, compared to a net loss of $10.1 million for the year ended December 31, 2023.
• ENDRA's disclosure controls and procedures were not effective as of December 31, 2024, due to a material weakness in internal control over financial reporting.

Risks

• ENDRA may not be able to successfully execute its business model.
• The company's TAEUS platform applications may not achieve adequate market acceptance.
• ENDRA has limited resources and depends on third parties to design and manufacture, and seek regulatory approval of, its TAEUS applications.
• Competition in the medical imaging market is intense, and ENDRA may be unable to successfully compete.
• The company is subject to risks associated with doing business outside of the United States, including changes in political and economic conditions, regulatory requirements, and currency exchange rates.
• ENDRA's stock price is subject to minimum requirements to remain listed on the Nasdaq Capital Market, and may be delisted if it does not maintain compliance with those requirements.

Future Outlook

ENDRA plans to submit a new De Novo request based on the completion of a clinical study to enable sales in the United States. The commencement of this study is subject to successful completion of current research and development activities. The company expects to commence product commercialization with a small direct sales and marketing team which will later engage and support larger channel partners and clinical customers in primary geographic markets initially in Europe, and later in the U.S. after FDA approval.

Management Comments

• Over the past several months, we have revisited and re-evaluated ENDRAs vision, purpose, and go-to-market strategy with respect to TAEUS.
• We are redefining TAEUS technology to make it more scalable and to improve its adoption in newly targeted large market segments.

Industry Context

The document highlights the growing burden of steatotic liver disease and the need for better diagnostics, as well as the emerging therapeutics for liver fat reduction, particularly with GLP-1 receptor agonists. It also discusses the diagnostic gaps and the urgent need for improved liver fat detection.

Comparison to Industry Standards

• The current non-invasive gold standard for liver fat measurement is magnetic resonance imaging (MRI), but its high cost, long procedural time, and limited accessibility make it impractical for routine screening.
• Alternative diagnostic methods such as ultrasound and blood tests also have notable limitations.
• Ultrasound, though widely available, currently lacks the accuracy needed for detecting liver fat, particularly in individuals with higher body mass indices.
• Blood tests, while non-invasive, suffer from low precision and reliability, making them insufficient for definitive diagnosis or monitoring treatment progress.
• Competitors include producers of CT and MRI systems that include multi-national corporations such as Royal Philips, Siemens AG and Fujifilm Corporation, many of whom also manufacture and sell ultrasound equipment.
• In the MASLD diagnosis market we will compete with makers of surgical biopsy tools, such as Cook Medical and Sterylab S.r.l.
• In the thermal ablation market, we will compete with manufacturers of surgical temperature probes, such as Medtronic plc and St. Jude Medical, Inc.

Management Changes

Related Party Transactions

• On May 2, 2023, the Company conducted a registered offering in which the Company sold 48 shares of its common stock and 24 warrants to the Companys director, Anthony DiGiandomenico, for cash at the public offering price, which was less than 5% of beneficial ownership in the Company.
• On October 17, 2023, the Company entered into a consulting agreement with one of its directors, Alex Tokman, pursuant to which Mr. Tokman provided commercialization services. Under the terms of the agreement, Mr. Tokman was compensated at a rate of $150 per hour for his services.
• On November 30, 2023, the Company entered into a Restricted Stock Agreement and Consulting Services Agreement, each with PatentVest, in exchange for certain services related to the Companys patent portfolio. PatentVest is a wholly-owned subsidiary of MDB Capital Holdings, LLC (MDB). Anthony DiGiandomenico, a member of the Companys board of directors, is the Chief of Transactions and a director of MDB.
• In September 2024 the Company began using IS Bookkeeping & Payroll which is a division of Impact Solve, LLC (dba Impact Solutions) an accounting and chief financial officer service firm. The Companys Chief Financial Officer works in a part-time capacity for the Company through Impact Solutions.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and the risk of stock price volatility.
• Employees may experience uncertainty due to the company's financial challenges and potential restructuring.
• Customers and partners may be affected by delays in product development and commercialization.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• ENDRA plans to submit a new De Novo request based on the completion of a clinical study to enable sales in the United States.
• The company expects to commence product commercialization with a small direct sales and marketing team which will later engage and support larger channel partners and clinical customers in primary geographic markets initially in Europe, and later in the U.S. after FDA approval.

Key Dates

Keywords

TAEUS, metabolic disease, GLP-1, liver fat, diagnostics, clinical trials, FDA, CE mark, subscription model, medical imaging, ENDRA